DELIVRA HEALTH BRANDS INC (DHB.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:DHB - CA24703H2019 - Common Stock
0.22 CAD
0 (0%)
We assign a fundamental rating of 3 out of 10 to DHB. DHB was compared to 30 industry peers in the Pharmaceuticals industry. The financial health of DHB is average, but there are quite some concerns on its profitability. DHB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
DHB had negative earnings in the past year.
In the past year DHB has reported a negative cash flow from operations.
In the past 5 years DHB reported 4 times negative net income.
DHB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -8.86%, DHB is in line with its industry, outperforming 46.67% of the companies in the same industry.
With a Return On Equity value of -18.62%, DHB perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.86% | ||
| ROE | -18.62% | ||
| ROIC | N/A |
ROA(3y)-1.81%
ROA(5y)-43.05%
ROE(3y)-5.55%
ROE(5y)-101.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of DHB (49.16%) is better than 66.67% of its industry peers.
DHB's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for DHB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.54%
GM growth 5Y20.78%
2. Health
2.1 Basic Checks
DHB does not have a ROIC to compare to the WACC, probably because it is not profitable.
DHB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, DHB has more shares outstanding
Compared to 1 year ago, DHB has a worse debt to assets ratio.
2.2 Solvency
DHB has an Altman-Z score of -19.26. This is a bad value and indicates that DHB is not financially healthy and even has some risk of bankruptcy.
DHB has a Altman-Z score of -19.26. This is amonst the worse of the industry: DHB underperforms 93.33% of its industry peers.
A Debt/Equity ratio of 0.43 indicates that DHB is not too dependend on debt financing.
DHB's Debt to Equity ratio of 0.43 is on the low side compared to the rest of the industry. DHB is outperformed by 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.26 |
ROIC/WACCN/A
WACC7.35%
2.3 Liquidity
DHB has a Current Ratio of 3.14. This indicates that DHB is financially healthy and has no problem in meeting its short term obligations.
DHB's Current ratio of 3.14 is fine compared to the rest of the industry. DHB outperforms 76.67% of its industry peers.
DHB has a Quick Ratio of 2.35. This indicates that DHB is financially healthy and has no problem in meeting its short term obligations.
DHB has a better Quick ratio (2.35) than 86.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 2.35 |
3. Growth
3.1 Past
DHB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -560.71%.
Looking at the last year, DHB shows a quite strong growth in Revenue. The Revenue has grown by 13.01% in the last year.
The Revenue has been growing by 11.44% on average over the past years. This is quite good.
EPS 1Y (TTM)-560.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.76%
Revenue 1Y (TTM)13.01%
Revenue growth 3Y17.99%
Revenue growth 5Y11.44%
Sales Q2Q%1.39%
3.2 Future
Based on estimates for the next years, DHB will show a very strong growth in Earnings Per Share. The EPS will grow by 49.00% on average per year.
DHB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.79% yearly.
EPS Next Y80%
EPS Next 2Y49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.99%
Revenue Next 2Y13.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DHB. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 19.42, which indicates a rather expensive current valuation of DHB.
Based on the Price/Forward Earnings ratio, DHB is valued a bit cheaper than 70.00% of the companies in the same industry.
DHB is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.42 |
4.2 Price Multiples
DHB's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.74 |
4.3 Compensation for Growth
DHB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as DHB's earnings are expected to grow with 49.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49%
EPS Next 3YN/A
5. Dividend
5.1 Amount
DHB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:DHB (12/24/2025, 7:00:00 PM)
0.22
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.86%
Inst Owner ChangeN/A
Ins Owners13.18%
Ins Owner ChangeN/A
Market Cap6.88M
Revenue(TTM)13.41M
Net Income(TTM)-806.00K
Analysts84.44
Price Target0.73 (231.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.42 | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.59 | ||
| P/tB | 1.59 | ||
| EV/EBITDA | 13.74 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY5.15%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.43
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.86% | ||
| ROE | -18.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.16% | ||
| FCFM | N/A |
ROA(3y)-1.81%
ROA(5y)-43.05%
ROE(3y)-5.55%
ROE(5y)-101.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.54%
GM growth 5Y20.78%
F-Score3
Asset Turnover1.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.42 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 2.35 | ||
| Altman-Z | -19.26 |
F-Score3
WACC7.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-560.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.76%
EPS Next Y80%
EPS Next 2Y49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.01%
Revenue growth 3Y17.99%
Revenue growth 5Y11.44%
Sales Q2Q%1.39%
Revenue Next Year13.99%
Revenue Next 2Y13.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year212.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.19%
OCF growth 3YN/A
OCF growth 5YN/A
DELIVRA HEALTH BRANDS INC / DHB.CA FAQ
Can you provide the ChartMill fundamental rating for DELIVRA HEALTH BRANDS INC?
ChartMill assigns a fundamental rating of 3 / 10 to DHB.CA.
What is the valuation status of DELIVRA HEALTH BRANDS INC (DHB.CA) stock?
ChartMill assigns a valuation rating of 3 / 10 to DELIVRA HEALTH BRANDS INC (DHB.CA). This can be considered as Overvalued.
What is the profitability of DHB stock?
DELIVRA HEALTH BRANDS INC (DHB.CA) has a profitability rating of 2 / 10.
Can you provide the financial health for DHB stock?
The financial health rating of DELIVRA HEALTH BRANDS INC (DHB.CA) is 4 / 10.